During the COVID-19 pandemic, oncology nurses have been the cornerstone of healthcare services, whether they are on the front lines offering compassionate care or in a leadership role developing and implementing new policies to promote better patient outcomes.
Results from 2 studies highlight the increasingly important role of germline testing in the management of patients with cancer. These findings were presented by Zsofia K. Stadler, MD, Medical Oncologist, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York City.
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) in Baltimore is a National Cancer Institute–designated comprehensive cancer center, a distinction that places it in the top tier of cancer institutions in the United States.
In an analysis of the phase 3 PRIMA study, niraparib monotherapy as first-line maintenance after platinum-based chemotherapy improved progression-free survival in women with newly diagnosed advanced ovarian cancer regardless of BRCA mutation status or homologous recombination status (deficient or proficient).
ASCO guidelines cite significant improvement in progression-free survival when PARP inhibitors are used as maintenance therapy or in the setting of recurrent disease in women with advanced ovarian cancer who have responded to platinum-based chemotherapy in the first line.